Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00004890 Completed - Kidney Cancer Clinical Trials

Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer

Start date: December 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2. PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.

NCT ID: NCT00004880 Completed - Kidney Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Kidney Cancer

Start date: June 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.

NCT ID: NCT00004856 Terminated - Clinical trials for Stage IV Bladder Cancer

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Start date: July 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

NCT ID: NCT00004244 Completed - Kidney Cancer Clinical Trials

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Start date: March 2000
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of interleukin-12 and interferon alfa in treating patients with metastatic kidney cancer or malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining interleukin-12 and interferon alfa may kill more cancer cells.

NCT ID: NCT00004223 Completed - Bladder Cancer Clinical Trials

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Start date: February 24, 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel and gemcitabine in treating patients who have progressive regional or metastatic bladder cancer.

NCT ID: NCT00004203 Completed - Bladder Cancer Clinical Trials

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Start date: February 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic bladder cancer.

NCT ID: NCT00004135 Completed - Kidney Cancer Clinical Trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Start date: February 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients who have metastatic kidney cancer or melanoma.

NCT ID: NCT00004095 Completed - Breast Cancer Clinical Trials

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: August 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan and gemcitabine in treating patients who have unresectable or metastatic solid tumors.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

NCT ID: NCT00003968 Completed - Kidney Cancer Clinical Trials

Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

Start date: June 1999
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have metastatic kidney cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.